Anxo Pharmaceutical Co., Ltd. (6677) Stock Statistics & Valuation Metrics
Total Valuation
Anxo Pharmaceutical Co., Ltd. has a market cap or net worth of TWD 1.18B. The enterprise value is ―.
- Market Cap
- TWD 1.18B
- Enterprise Value
- ―
Share Statistics
Anxo Pharmaceutical Co., Ltd. has 56,038,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 56,038,950
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Anxo Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -1.80%.
- Return on Equity (ROE)
- -0.03
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -1.80%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 56.22M
- Profits Per Employee
- -2.28M
- Employee Count
- 15
- Asset Turnover
- 0.41
- Inventory Turnover
- 2.14
Valuation Ratios
The current PE Ratio of Anxo Pharmaceutical Co., Ltd. is -58.11. Anxo Pharmaceutical Co., Ltd.’s PEG ratio is -0.87.
- PE Ratio
- -58.11
- PS Ratio
- 1.37
- PB Ratio
- 1.20
- Price to FCF
- -49.71
- Price to Operating Cash Flow
- 21.18
- PEG Ratio
- -0.87
Income Statement
In the last 12 months, Anxo Pharmaceutical Co., Ltd. had revenue of 843.26M and earned -34.13M in profits. Earnings per share was -0.61.
- Revenue
- 843.26M
- Gross Profit
- 300.18M
- Operating Income
- -43.69M
- Pretax Income
- -45.60M
- Net Income
- -34.13M
- EBITDA
- 32.51M
- Earnings Per Share (EPS)
- -0.61
Cash Flow
In the last 12 months, operating cash flow was 55.76M and capital expenditures -79.97M, giving a free cash flow of -24.21M billion.
- Operating Cash Flow
- 55.76M
- Free Cash Flow
- -24.21M
- Free Cash Flow per Share
- -0.44
Dividends & Yields
Anxo Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.01%
- Earnings Yield
- -1.73%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- -15.94%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 54.83
- Average Volume (3m)
- 122.19K
Financial Position
Anxo Pharmaceutical Co., Ltd. as a current ratio of 1.57, with Debt / Equity ratio of 74.11%
- Current Ratio
- 1.57
- Quick Ratio
- 1.10
- Debt to Market Cap
- 0.69
- Net Debt to EBITDA
- 10.99
- Interest Coverage Ratio
- -2.63
Taxes
In the past 12 months, Anxo Pharmaceutical Co., Ltd. has paid -10.47M in taxes.
- Income Tax
- -10.47M
- Effective Tax Rate
- 0.23
Enterprise Valuation
Anxo Pharmaceutical Co., Ltd. EV to EBITDA ratio is 46.25, with an EV/FCF ratio of -66.65.
- EV to Sales
- 1.84
- EV to EBITDA
- 46.25
- EV to Free Cash Flow
- -66.65
- EV to Operating Cash Flow
- 28.94
Balance Sheet
Anxo Pharmaceutical Co., Ltd. has TWD 334.82M in cash and marketable securities with TWD 741.47M in debt, giving a net cash position of -TWD 406.65M billion.
- Cash & Marketable Securities
- TWD 334.82M
- Total Debt
- TWD 741.47M
- Net Cash
- -TWD 406.65M
- Net Cash Per Share
- -TWD 7.26
- Tangible Book Value Per Share
- TWD 19.26
Margins
Gross margin is 36.62%, with operating margin of -4.29%, and net profit margin of -2.33%.
- Gross Margin
- 36.62%
- Operating Margin
- -4.29%
- Pretax Margin
- -3.22%
- Net Profit Margin
- -2.33%
- EBITDA Margin
- 3.97%
- EBIT Margin
- -4.29%
Analyst Forecast
The average price target for Anxo Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -0.49%
- EPS Growth Forecast
- 51.79%
